Microtubule dynamics inhibitor

Microtubule dynamics inhibitors are a class of therapeutic agents that interfere with the dynamic assembly and disassembly processes of microtubles—cytoskeletal polymers composed primarily of α/β-tubulin heterodimers essential for many cellular functions including chromosome segregation during mitosis. By disrupting these processes either through stabilization or destabilization mechanisms, these drugs induce cell cycle arrest predominantly at the M phase leading to apoptotic cell death. This mechanism exploits the heightened sensitivity of rapidly dividing cancer cells compared to normal cells. Clinically important examples include taxanes like paclitaxel which stabilize microtubles preventing their disassembly, and vinca alkaloids like vinblastine which prevent polymer formation causing spindle disruption. Beyond oncology applications in various solid tumors and hematologic cancers, some agents also treat other diseases such as gout by inhibiting inflammatory pathways linked with tubulin function. Despite proven efficacy over decades in cancer chemotherapy regimens worldwide, challenges remain including toxicity management and overcoming resistance mechanisms[1][2][4][6][7][8][9].

Other names

Mitotic inhibitormicrotubule inhibitortubulin inhibitormicrotubule-targeting agent (MTA)antimitotic agent

Two main strategies: 1. *Microtubule stabilizers* — bind β-tubulin subunits to promote polymerization and stabilize microtubules against depolymerization; this disrupts normal dynamic instability required for mitosis leading to cell cycle arrest in M phase and apoptosis. Example drugs include taxanes like paclitaxel. 2. *Microtubule destabilizers* — bind β-tubulin at different sites preventing polymerization or promoting depolymerization; this inhibits mitotic spindle formation causing mitotic arrest and apoptosis. Examples include vinca alkaloids and colchicine. Additionally: - Some novel agents inhibit tubulin polymerization via unique binding sites distinct from classical ones. - Emerging approaches involve targeted degradation of microtubule-associated proteins.